Biogen primes investors for a lecanemab data dredge
Clarity AD could yield a range of scenarios, and Biogen isn’t ruling out dredging secondary endpoints if the primary fails.
Ultragenyx sees enough in Angelman
The group buys out its partner Genetx, but inconsistent data spook investors.
Unpacking Royalty Pharma
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
